US · Healthcare · Medical Devices
EPS came in at 0.08 against a street estimate of 0.03 — a beat of 166.7%.
Analysts rate Neogen Corporation a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $13.33.
CONFIDENT Food Safety returned to 5.8% core growth, highest since 2023. Animal Safety stabilized post-supply crisis. FY27 guidance $880–885M revenue, $180–182M EBITDA—above Street. Heavy R&D investment underway; Petrifilm transition on track. Q4 FY26 U.S. and international balanced; LatAm strongest growth driver; FX expected -1% headwind FY27. Analysts pressed on margin expansion disconnect and segment guidance. Management emphasized heavy innovation investment timing (18–24 month cycles require now spending) and conservative Street credibility goal. Also clarified Genomics inclusion in consensus. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 14.96% |
| Vanguard Portfolio Management, LLC | 5.88% |
| T. Rowe Price Investment Management,Inc. | 4.66% |
| Dimensional Fund Advisors, Inc. | 4.51% |
| Vanguard Capital Management, LLC | 4.39% |
| ING Groep NV | 4.08% |
| Gates Capital Management Inc | 4.01% |
| State Street Corp | 3.94% |
| Document | Date |
|---|---|
| Proxy statement · Q1 FY2027 NEOGEN CORPORATION PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of three Class III directors for three-year t | 2026-08-21 |
| Board / officer change · Q1 FY2027 NEOGEN CORPORATION – 8-K FILING SUMMARY HEADLINE NUMBERS • Filing Date: August 7, 2026 (Event Date: August 3, 2026) • Company: Neogen Corporation (T | 2026-08-07 |
| Annual report FY2026 NEOGEN CORPORATION – 10-K SUMMARY FOR RETAIL INVESTORS Fiscal Year Ended May 31, 2026 --- HEADLINE NUMBERS • Market Value (as of Nov 30, 2025): $97 | 2026-07-30 |
| Results announced · Q1 FY2027 NEOGEN CORPORATION – FY2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • FY2026 Total Revenue: $870.4 million, down 2.7% year-over-year (prior year: | 2026-07-30 |
| Reg FD disclosure · Q4 FY2026 NEOGEN CORPORATION 8-K SUMMARY HEADLINE NUMBERS • No specific financial figures disclosed in this 8-K filing • Company is Neogen Corporation, traded | 2026-04-20 |
| Quarterly report · Q3 FY2026 NEOGEN CORPORATION - 10-Q SUMMARY Period Ended February 28, 2026 --- HEADLINE NUMBERS • Total Revenues (9 months): $645.1 million vs $669.2 million | 2026-04-09 |
| Results announced · Q4 FY2026 NEOGEN CORPORATION – Q3 FY2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q3 FY2026 total revenue: $211.2 million, down 4.4% year-over-year from $221.0 mi | 2026-04-09 |
| Quarterly report · Q2 FY2026 NEOGEN CORPORATION – 10-Q SUMMARY FOR RETAIL INVESTORS Period Ended November 30, 2025 --- HEADLINE NUMBERS • Total Revenues (6 months): $433.9 mill | 2026-01-08 |
Readable in the app.
| Announcement | Date |
|---|---|
| FY2027 financial guidance provided for revenue and Adjusted EBITDA Neogen Corporation reported mixed fiscal year 2026 results. Full-year revenue was $870.4 million, down 2.7% year-over-year, though core growth (excluding divestitures) reached 1.9%. Fourth q | 2026-07-30 |
| Raised fiscal year 2026 revenue outlook; maintained Adjusted EBITDA guidance Neogen Corporation reported Q3 FY2026 revenue of $211.2 million, down 4.4% year-over-year, reflecting mixed business performance. Food Safety grew modestly at 2.6% core growth (4.0%), driven | 2026-04-09 |
| Q2 2026 results; raises FY 2026 revenue and Adjusted EBITDA guidance Neogen Corporation reported Q2 2026 results showing mixed near-term performance but positive strategic momentum. Revenue declined 2.8% year-over-year to $224.7 million, but core revenue (exc | 2026-01-08 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Neogen Corporation — free to start.
Google PlayApp StoreData updated 2026-09-18.